Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immunotherapies and vaccines - Scorpius Holdings

Next Previous
Drug Profile

Research programme: immunotherapies and vaccines - Scorpius Holdings

Alternative Names: Anti-TLIA - NightHawk Biosciences; Anti-TNFRSF25 - Heat Biologics; Fc-OX40L; HS 310 - NightHawk Biosciences; HS-120; HS-210; HS-310; HS-HCV; HS-HIV; HS-HIV/SIV; HS-HIV1; HS-O1; HS-P1; IN-A1; Inhibicor; Medicor

Latest Information Update: 09 Feb 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heat Biologics
  • Developer Heat Biologics; Scorpius Holdings
  • Class AIDS vaccines; Antibodies; Cancer vaccines; Cell therapies; Heat shock proteins; Immunoglobulin fusion proteins; Tumour cell vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunostimulants; Tumour necrosis factor ligand superfamily member 15 inhibitors; Tumour necrosis factor member 25 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Asthma; Autoimmune disorders; Hepatitis C; HIV-1 infections; Transplant rejection

Most Recent Events

  • 06 Feb 2024 NightHawk Biosciences is now called Scorpius Holdings
  • 27 Jan 2023 NightHawk Biosciences terminates its licensing agreement with University of Miami for gp96 and TNFRSF25 platforms
  • 03 May 2022 Heat Biologics is now called NightHawk Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top